NO301231B1 - 2'-deoksy-2'-fluorcoformycin og stereoisomerer av disse - Google Patents
2'-deoksy-2'-fluorcoformycin og stereoisomerer av disse Download PDFInfo
- Publication number
- NO301231B1 NO301231B1 NO941800A NO941800A NO301231B1 NO 301231 B1 NO301231 B1 NO 301231B1 NO 941800 A NO941800 A NO 941800A NO 941800 A NO941800 A NO 941800A NO 301231 B1 NO301231 B1 NO 301231B1
- Authority
- NO
- Norway
- Prior art keywords
- deoxy
- compound
- fluoro
- fluorocoformycin
- group
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 340
- 125000001153 fluoro group Chemical group F* 0.000 claims description 23
- 229910052731 fluorine Inorganic materials 0.000 claims description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 22
- NKWCGTOZTHZDHB-UHFFFAOYSA-N 1h-imidazol-1-ium-4-carboxylate Chemical compound OC(=O)C1=CNC=N1 NKWCGTOZTHZDHB-UHFFFAOYSA-N 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 125000000824 D-ribofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@]1([H])O[H] 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- SUJOYGAGMLMPTL-LIJDECJQSA-N 5-amino-1-[(2r,3r,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazole-4-carboxylic acid Chemical compound NC1=C(C(O)=O)N=CN1[C@H]1[C@H](F)[C@H](O)[C@@H](CO)O1 SUJOYGAGMLMPTL-LIJDECJQSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 66
- 238000003786 synthesis reaction Methods 0.000 abstract description 65
- 102000055025 Adenosine deaminases Human genes 0.000 abstract description 27
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 abstract description 26
- 230000002401 inhibitory effect Effects 0.000 abstract description 20
- 239000000543 intermediate Substances 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 12
- 102000004190 Enzymes Human genes 0.000 abstract description 11
- 108090000790 Enzymes Proteins 0.000 abstract description 11
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract description 4
- YYVZPZJEMLBIGM-TWMKSMIVSA-N [(2r,3r,4s,5r)-3-benzoyloxy-5-bromo-4-fluorooxolan-2-yl]methyl benzoate Chemical compound C([C@H]1O[C@H](Br)[C@H]([C@@H]1OC(=O)C=1C=CC=CC=1)F)OC(=O)C1=CC=CC=C1 YYVZPZJEMLBIGM-TWMKSMIVSA-N 0.000 abstract description 3
- 238000003541 multi-stage reaction Methods 0.000 abstract description 3
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 88
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
- 238000006243 chemical reaction Methods 0.000 description 66
- 239000000203 mixture Substances 0.000 description 63
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 61
- -1 D-ribofuranosyl halide Chemical class 0.000 description 49
- 238000000034 method Methods 0.000 description 45
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 36
- 239000006188 syrup Substances 0.000 description 31
- 235000020357 syrup Nutrition 0.000 description 31
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 27
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 22
- 239000007787 solid Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- YOOVTUPUBVHMPG-LODYRLCVSA-O coformycin(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C([NH+]=CNC[C@H]2O)=C2N=C1 YOOVTUPUBVHMPG-LODYRLCVSA-O 0.000 description 19
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 17
- YOOVTUPUBVHMPG-UHFFFAOYSA-N Coformycin Natural products OC1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 YOOVTUPUBVHMPG-UHFFFAOYSA-N 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
- 238000000921 elemental analysis Methods 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 238000001228 spectrum Methods 0.000 description 14
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 13
- 238000010898 silica gel chromatography Methods 0.000 description 13
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000010586 diagram Methods 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 8
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 229960002340 pentostatin Drugs 0.000 description 8
- KBHMEHLJSZMEMI-UHFFFAOYSA-N Formycin A Natural products N1N=C2C(N)=NC=NC2=C1C1OC(CO)C(O)C1O KBHMEHLJSZMEMI-UHFFFAOYSA-N 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 238000010531 catalytic reduction reaction Methods 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- KBHMEHLJSZMEMI-KSYZLYKTSA-N formycin A Chemical compound N=1NC=2C(N)=NC=NC=2C=1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O KBHMEHLJSZMEMI-KSYZLYKTSA-N 0.000 description 7
- 150000002460 imidazoles Chemical class 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 238000007664 blowing Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000003456 ion exchange resin Substances 0.000 description 5
- 229920003303 ion-exchange polymer Polymers 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- CKUQKAYPZHYJGS-UHFFFAOYSA-N CCOC=NCC(=O)OC(C)C#N Chemical compound CCOC=NCC(=O)OC(C)C#N CKUQKAYPZHYJGS-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 229940045799 anthracyclines and related substance Drugs 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 3
- XRXCXDXUNCLIFR-IOVATXLUSA-N (2r,3r,4s)-5-azido-4-fluoro-2-(hydroxymethyl)oxolan-3-ol Chemical compound OC[C@H]1OC(N=[N+]=[N-])[C@@H](F)[C@@H]1O XRXCXDXUNCLIFR-IOVATXLUSA-N 0.000 description 2
- UUSMORJRYZFLSS-SQOUGZDYSA-N (2r,3s,4s,5r)-2-amino-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound N[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O UUSMORJRYZFLSS-SQOUGZDYSA-N 0.000 description 2
- YOFDHOWPGULAQF-MQJDWESPSA-N (7s,9s)-9-acetyl-6,7,9,11-tetrahydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound C1[C@@](O)(C(C)=O)C[C@H](O)C2=C1C(O)=C1C(=O)C(C=CC=C3OC)=C3C(=O)C1=C2O YOFDHOWPGULAQF-MQJDWESPSA-N 0.000 description 2
- NOUDGPISLXECAJ-UHFFFAOYSA-N 1h-imidazole-5-carbonyl chloride Chemical compound ClC(=O)C1=CNC=N1 NOUDGPISLXECAJ-UHFFFAOYSA-N 0.000 description 2
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- OLXZPDWKRNYJJZ-UHFFFAOYSA-N 5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(CO)O1 OLXZPDWKRNYJJZ-UHFFFAOYSA-N 0.000 description 2
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 2
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 2
- YOFDHOWPGULAQF-UHFFFAOYSA-N Daunomycin-Aglycone Natural products C1C(O)(C(C)=O)CC(O)C2=C1C(O)=C1C(=O)C(C=CC=C3OC)=C3C(=O)C1=C2O YOFDHOWPGULAQF-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 125000006355 carbonyl methylene group Chemical group [H]C([H])([*:2])C([*:1])=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 2
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JEHCHYAKAXDFKV-UHFFFAOYSA-J lead tetraacetate Chemical compound CC(=O)O[Pb](OC(C)=O)(OC(C)=O)OC(C)=O JEHCHYAKAXDFKV-UHFFFAOYSA-J 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 238000007248 oxidative elimination reaction Methods 0.000 description 2
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ULRUFWVRASYVEG-JDJSBBGDSA-N (2r,3r,4r)-4-fluoro-2-(hydroxymethyl)-5-methoxyoxolan-3-ol Chemical compound COC1O[C@H](CO)[C@@H](O)[C@H]1F ULRUFWVRASYVEG-JDJSBBGDSA-N 0.000 description 1
- ULRUFWVRASYVEG-KVTDHHQDSA-N (2r,3r,4r,5r)-4-fluoro-2-(hydroxymethyl)-5-methoxyoxolan-3-ol Chemical compound CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1F ULRUFWVRASYVEG-KVTDHHQDSA-N 0.000 description 1
- ULRUFWVRASYVEG-KAZBKCHUSA-N (2r,3r,4r,5s)-4-fluoro-2-(hydroxymethyl)-5-methoxyoxolan-3-ol Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H]1F ULRUFWVRASYVEG-KAZBKCHUSA-N 0.000 description 1
- UUSMORJRYZFLSS-TXICZTDVSA-N (2r,3r,4s,5r)-2-amino-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound N[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UUSMORJRYZFLSS-TXICZTDVSA-N 0.000 description 1
- RTUWTJAKZMHWBQ-SOOFDHNKSA-N (3r,4r,5r)-3-fluoro-5-(hydroxymethyl)oxolane-2,4-diol Chemical compound OC[C@H]1OC(O)[C@H](F)[C@@H]1O RTUWTJAKZMHWBQ-SOOFDHNKSA-N 0.000 description 1
- JYWSHPMZFVPRRF-AMFMTJJISA-N (8r)-3-[(2r,3r,4r,5r)-3-chloro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7,8-dihydro-4h-imidazo[4,5-d][1,3]diazepin-8-ol Chemical compound Cl[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 JYWSHPMZFVPRRF-AMFMTJJISA-N 0.000 description 1
- JYWSHPMZFVPRRF-UHFFFAOYSA-N 2'-chloropentostatin Natural products ClC1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 JYWSHPMZFVPRRF-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 1
- 102000005234 Adenosylhomocysteinase Human genes 0.000 description 1
- 108020002202 Adenosylhomocysteinase Proteins 0.000 description 1
- IBZGBXXTIGCACK-CWKPULSASA-N Adriamycinone Chemical compound C1[C@@](O)(C(=O)CO)C[C@H](O)C2=C1C(O)=C1C(=O)C(C=CC=C3OC)=C3C(=O)C1=C2O IBZGBXXTIGCACK-CWKPULSASA-N 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 235000010893 Bischofia javanica Nutrition 0.000 description 1
- 240000005220 Bischofia javanica Species 0.000 description 1
- 102100037631 Centrin-2 Human genes 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 125000003317 D-arabinofuranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@@]([H])(O[H])[C@]1([H])O[H] 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229930191892 Formycin Natural products 0.000 description 1
- 101000880516 Homo sapiens Centrin-2 Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229930182474 N-glycoside Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- YTAHJIFKAKIKAV-XNMGPUDCSA-N [(1R)-3-morpholin-4-yl-1-phenylpropyl] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound O=C1[C@H](N=C(C2=C(N1)C=CC=C2)C1=CC=CC=C1)NC(O[C@H](CCN1CCOCC1)C1=CC=CC=C1)=O YTAHJIFKAKIKAV-XNMGPUDCSA-N 0.000 description 1
- SQLPXBURVBZOJC-JKUQZMGJSA-N [(2r,3r,4r)-4-fluoro-1,3-dihydroxy-5-oxopentan-2-yl] formate Chemical compound O=CO[C@H](CO)[C@@H](O)[C@@H](F)C=O SQLPXBURVBZOJC-JKUQZMGJSA-N 0.000 description 1
- FHKKLEXAYCOKAG-IKVWTGGYSA-N [(2r,3r,4r,5r)-5-acetyloxy-3-benzoyloxy-4-fluorooxolan-2-yl]methyl benzoate Chemical compound C([C@H]1O[C@@H]([C@@H]([C@@H]1OC(=O)C=1C=CC=CC=1)F)OC(=O)C)OC(=O)C1=CC=CC=C1 FHKKLEXAYCOKAG-IKVWTGGYSA-N 0.000 description 1
- 150000004075 acetic anhydrides Chemical class 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 239000002487 adenosine deaminase inhibitor Substances 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910021386 carbon form Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 208000035196 congenital hypomyelinating 2 neuropathy Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- UHOVQNZJYSORNB-MICDWDOJSA-N deuteriobenzene Chemical compound [2H]C1=CC=CC=C1 UHOVQNZJYSORNB-MICDWDOJSA-N 0.000 description 1
- VOJXZEPEOLREJH-INTNWOOBSA-N diazonio-[2-[5-(dimethylaminomethylideneamino)-1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]imidazol-4-yl]-2-oxoethyl]azanide Chemical compound CN(C)C=NC1=C(C(=O)C[N-][N+]#N)N=CN1[C@H]1[C@@H](F)[C@H](O)[C@@H](CO)O1 VOJXZEPEOLREJH-INTNWOOBSA-N 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 238000005858 glycosidation reaction Methods 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000006140 methanolysis reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000006825 purine synthesis Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- VDZXAOBGHPKGCS-UHFFFAOYSA-M sodium;1,4-dioxane;hydroxide Chemical compound [OH-].[Na+].C1COCCO1 VDZXAOBGHPKGCS-UHFFFAOYSA-M 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C07H5/06—Aminosugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/02—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to halogen
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
- F01K—STEAM ENGINE PLANTS; STEAM ACCUMULATORS; ENGINE PLANTS NOT OTHERWISE PROVIDED FOR; ENGINES USING SPECIAL WORKING FLUIDS OR CYCLES
- F01K23/00—Plants characterised by more than one engine delivering power external to the plant, the engines being driven by different fluids
- F01K23/02—Plants characterised by more than one engine delivering power external to the plant, the engines being driven by different fluids the engine cycles being thermally coupled
- F01K23/06—Plants characterised by more than one engine delivering power external to the plant, the engines being driven by different fluids the engine cycles being thermally coupled combustion heat from one cycle heating the fluid in another cycle
- F01K23/10—Plants characterised by more than one engine delivering power external to the plant, the engines being driven by different fluids the engine cycles being thermally coupled combustion heat from one cycle heating the fluid in another cycle with exhaust fluid of one cycle heating the fluid in another cycle
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Combustion & Propulsion (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mechanical Engineering (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP35258891 | 1991-11-14 | ||
PCT/JP1992/001489 WO1993010137A1 (en) | 1991-11-14 | 1992-11-13 | 2'-deoxy-2'-fluorocoformycin and stereoisomers thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
NO941800D0 NO941800D0 (no) | 1994-05-13 |
NO941800L NO941800L (no) | 1994-07-04 |
NO301231B1 true NO301231B1 (no) | 1997-09-29 |
Family
ID=18425076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO941800A NO301231B1 (no) | 1991-11-14 | 1994-05-13 | 2'-deoksy-2'-fluorcoformycin og stereoisomerer av disse |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0643069B1 (da) |
JP (1) | JP3030087B2 (da) |
KR (1) | KR0163799B1 (da) |
AT (1) | ATE149510T1 (da) |
AU (1) | AU661520B2 (da) |
CA (1) | CA2122815C (da) |
DE (1) | DE69218005T2 (da) |
DK (1) | DK0643069T3 (da) |
ES (1) | ES2099841T3 (da) |
NO (1) | NO301231B1 (da) |
WO (1) | WO1993010137A1 (da) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09241294A (ja) * | 1996-03-07 | 1997-09-16 | Microbial Chem Res Found | 2′−デオキシ−2′−ハロコホルマイシン又はその立体異性体の製造法 |
JP6045641B1 (ja) * | 2015-06-04 | 2016-12-14 | 株式会社 資生堂 | 化粧容器 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4625020A (en) * | 1983-11-18 | 1986-11-25 | Bristol-Myers Company | Nucleoside process |
ATE34176T1 (de) * | 1984-03-16 | 1988-05-15 | Warner Lambert Co | 2'-chloropentostatin, eine diese verbindung enthaltende pharmazeutische zusammensetzung und ein mikroorganismus zur herstellung dieser verbindung. |
JPS61199797A (ja) * | 1985-02-28 | 1986-09-04 | Kitasato Inst:The | 新規化合物アデクロリンおよびその製造法 |
JPH0631298B2 (ja) * | 1985-12-18 | 1994-04-27 | 財団法人微生物化学研究会 | 新規アンスラサイクリン誘導体,抗腫瘍剤,及び製造法 |
JPH0798832B2 (ja) * | 1987-05-01 | 1995-10-25 | 財団法人微生物化学研究会 | イミダゾジアゼピン誘導体 |
-
1992
- 1992-11-13 JP JP5509148A patent/JP3030087B2/ja not_active Expired - Lifetime
- 1992-11-13 KR KR1019940701645A patent/KR0163799B1/ko not_active IP Right Cessation
- 1992-11-13 ES ES92923538T patent/ES2099841T3/es not_active Expired - Lifetime
- 1992-11-13 DE DE69218005T patent/DE69218005T2/de not_active Expired - Fee Related
- 1992-11-13 AT AT92923538T patent/ATE149510T1/de not_active IP Right Cessation
- 1992-11-13 AU AU29318/92A patent/AU661520B2/en not_active Ceased
- 1992-11-13 EP EP92923538A patent/EP0643069B1/en not_active Expired - Lifetime
- 1992-11-13 DK DK92923538.0T patent/DK0643069T3/da active
- 1992-11-13 CA CA002122815A patent/CA2122815C/en not_active Expired - Fee Related
- 1992-11-13 WO PCT/JP1992/001489 patent/WO1993010137A1/ja active IP Right Grant
-
1994
- 1994-05-13 NO NO941800A patent/NO301231B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0643069B1 (en) | 1997-03-05 |
AU661520B2 (en) | 1995-07-27 |
JPH06511062A (ja) | 1994-12-08 |
DE69218005T2 (de) | 1997-10-16 |
EP0643069A1 (en) | 1995-03-15 |
JP3030087B2 (ja) | 2000-04-10 |
EP0643069A4 (en) | 1994-11-22 |
CA2122815C (en) | 1998-09-15 |
NO941800L (no) | 1994-07-04 |
DE69218005D1 (de) | 1997-04-10 |
KR0163799B1 (ko) | 1998-11-16 |
WO1993010137A1 (en) | 1993-05-27 |
ES2099841T3 (es) | 1997-06-01 |
AU2931892A (en) | 1993-06-15 |
CA2122815A1 (en) | 1993-05-27 |
DK0643069T3 (da) | 1997-09-15 |
NO941800D0 (no) | 1994-05-13 |
ATE149510T1 (de) | 1997-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU597483B2 (en) | Desazapurine-nucleoside derivatives, processes for the preparation thereof, pharmaceutical compositions containing them and the use thereof for nucleic acid sequencing and as antiviral agents | |
Urata et al. | Synthesis and properties of mirror-image DNA | |
US6211158B1 (en) | Desazapurine-nucleotide derivatives, processes for the preparation thereof, pharmaceutical compositions containing them and the use thereof for nucleic acid sequencing and as antiviral agents | |
IE902665A1 (en) | Nucleoside derivatives and pharmaceutical compositions¹containing them | |
US5661136A (en) | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents | |
AU2003300901A1 (en) | Process for the production of 2'-branched nucleosides | |
US3225029A (en) | Process for the preparation of nucleosides and products obtained thereby | |
Montgomery et al. | 9-(2-Deoxy-2-fluoro-. beta.-D-arabinofuranosyl) guanine: a metabolically stable cytotoxic analogue of 2'-deoxyguanosine | |
Mikhailov et al. | Synthesis of 2′-O-α-d-ribofuranosyladenosine, monomeric unit of poly (ADP–ribose) | |
JPH06228186A (ja) | 2’−デオキシ−(2’s)−アルキルピリミジンヌクレオシド誘導体 | |
US5811408A (en) | 2'-deoxy-2'-(substituted or unsubstituted)methylidene-4'-thionucleosides | |
Chu et al. | Nucleosides. 104. Synthesis of 4-amino-5-(D-ribofuranosyl) pyrimidine C-nucleosides from 2-(2, 3-O-isopropylidene-5-O-trityl-D-ribofuranosyl) acetonitrile | |
Butkus et al. | Synthesis and physical characterization of DNA fragments containing N4-methylcytosine and 5-methylcytosine | |
US5886167A (en) | 2'-deoxy-2'-epi-2'-fluorocoformycin | |
JPH0853490A (ja) | 2’−デオキシ−2’,2’−ジハロゲノ−4’−チオヌクレオシド | |
NO301231B1 (no) | 2'-deoksy-2'-fluorcoformycin og stereoisomerer av disse | |
Sivets et al. | Synthesis of 2-fluoro-substituted and 2, 6-modified purine 2′, 3′-dideoxy-2′, 3′-difluoro-d-arabinofuranosyl nucleosides from d-xylose | |
EP0794194B1 (en) | A process for the preparation of 2'-deoxy-2'-halocoformycins or stereoisomers thereof | |
Ueda et al. | Synthesis of 8-Alkyladenosines, 8, 2'-Anhydro-8-hydroxymethyl-9-(β-D-arabinofuranosyl) adenine and Related Compounds (Nucleosides and Nucleotides. LVIII) | |
Shuto et al. | New Neplanocin Anallogues. VIII. Synthesis and Biological Activity of 6'-C-Ethyl,-Ethenyl, and-Ethynyl Derivatives of Neplanocin A | |
CA2425264A1 (en) | Tumor proliferation inhibitors | |
JPH06211890A (ja) | 2’−デオキシ−2’(s)−置換アルキルシチジン誘導体 | |
Martinez et al. | Structure and properties of some D-arabino-and D-xylopyranosyladenines | |
RU2748103C1 (ru) | Средство для ингибирования фермента тирозил-ДНК-фосфодиэстеразы 1 человека на основе производных пентафуранозилнуклеозидов | |
ITOH et al. | Studies on the Chemical Synthesis of Potential Antimetabolites. XXXIV. Apparent Discrepancy among Reported Proton Nuclear Magnetic Resonance Spectra of 3-Deazaadenosine Is Actually a Reflection of a Difference in Molecular Species |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |